[go: up one dir, main page]

AU8109794A - 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists - Google Patents

7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists

Info

Publication number
AU8109794A
AU8109794A AU81097/94A AU8109794A AU8109794A AU 8109794 A AU8109794 A AU 8109794A AU 81097/94 A AU81097/94 A AU 81097/94A AU 8109794 A AU8109794 A AU 8109794A AU 8109794 A AU8109794 A AU 8109794A
Authority
AU
Australia
Prior art keywords
imidazo
pyrazine
receptor antagonists
nmda receptor
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU81097/94A
Inventor
Jean-Claude Aloup
Francois Audiau
Dominique Damour
Arielle Genevois-Borella
Patrick Jimonet
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU8109794A publication Critical patent/AU8109794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU81097/94A 1993-11-05 1994-11-02 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists Abandoned AU8109794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9313164 1993-11-05
FR9313164A FR2711993B1 (en) 1993-11-05 1993-11-05 Drugs containing 7H-imidazol [1,2-a] pyrazine-8-one derivatives, new compounds and their preparation.
PCT/FR1994/001268 WO1995012594A1 (en) 1993-11-05 1994-11-02 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
AU8109794A true AU8109794A (en) 1995-05-23

Family

ID=9452533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81097/94A Abandoned AU8109794A (en) 1993-11-05 1994-11-02 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists

Country Status (7)

Country Link
EP (1) EP0726900A1 (en)
JP (1) JPH09504539A (en)
AU (1) AU8109794A (en)
FR (1) FR2711993B1 (en)
IL (1) IL111526A0 (en)
WO (1) WO1995012594A1 (en)
ZA (1) ZA948592B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040155A1 (en) * 1995-06-07 1996-12-19 The Johns Hopkins University Use of specific acpa derivative (npc-17742) for the treatment of ischemia
US6919340B2 (en) 2002-04-19 2005-07-19 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
BRPI0922225B1 (en) 2008-12-08 2022-01-11 Gilead Connecticut, Inc. SYK IMIDAZOPYRAZINE INHIBITORS, PHARMACEUTICAL COMPOSITION, AND COMPOUND USE
PE20120121A1 (en) 2008-12-08 2012-02-20 Gilead Connecticut Inc IMIDAZOPYRAZINE DERIVATIVES AS SYK INHIBITORS
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
KR101717809B1 (en) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 Imidazopyridines syk inhibitors
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
UA115815C2 (en) 2013-07-30 2017-12-26 Гіліад Коннектікут, Інк. COMPOSITION BASED ON SYK INHIBITORS
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
CA2932726C (en) 2013-12-04 2019-06-04 Gilead Sciences, Inc. Methods for treating cancers with entospletinib
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (en) 2013-12-23 2019-06-11 美商基利科學股份有限公司 Syk inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PT3105226T (en) 2014-02-13 2019-11-06 Incyte Corp CYCLOPROPYLAMINS AS LSD1 INHIBITORS
ME03654B (en) 2014-02-13 2020-07-20 Incyte Corp CYCLOPROPYLAMINE AS LSD1 INHIBITORS
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
EP3169366A1 (en) 2014-07-14 2017-05-24 Gilead Sciences, Inc. Combinations for treating cancers
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
KR102710120B1 (en) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Salt of LSD1 inhibitor
AR109452A1 (en) 2016-04-22 2018-12-12 Incyte Corp PHARMACEUTICAL FORMULATION OF AN LSD1 INHIBITOR AND TREATMENT METHOD
CN115028640A (en) 2017-08-25 2022-09-09 吉利德科学公司 Polymorphic forms of a SYK inhibitor
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN113950479A (en) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 Solid forms of condensed pyrazines as SYK inhibitors
JPWO2023042887A1 (en) 2021-09-15 2023-03-23
US20250281474A1 (en) 2021-09-15 2025-09-11 University Of The Ryukyus Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3767793A (en) * 1992-04-03 1993-11-08 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
FR2696466B1 (en) * 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa 5H, 10H-imidazo [1,2-a] indeno [1,2-e] pyrazine-4-one derivatives, their preparation and the medicaments containing them.

Also Published As

Publication number Publication date
IL111526A0 (en) 1995-01-24
EP0726900A1 (en) 1996-08-21
ZA948592B (en) 1995-06-23
FR2711993A1 (en) 1995-05-12
JPH09504539A (en) 1997-05-06
FR2711993B1 (en) 1995-12-01
WO1995012594A1 (en) 1995-05-11

Similar Documents

Publication Publication Date Title
AU8109794A (en) 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists
AU8069291A (en) Substituted 1-h-pyrrolo(2,3-b)pyridine-3-carboxamides
AU2524995A (en) Neurokinine (tachykinine) antagonists
AU660321B2 (en) 1,2-dihydro-2-oxopyridine
AU5276696A (en) Imidazo{1,2-a}pyridine derivatives
AU2734297A (en) Multi-site network database
AU5603094A (en) N,n-diacylpiperazine tachykinin antagonists
AU3665793A (en) Fibrinogen receptor antagonists
AU2042495A (en) Thieno(1,5)benzodiazepine use
AU6781194A (en) 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
HUP9600106A3 (en) 2,9-disubstituted purin-6-one derivatives
AU7447896A (en) Processes for the preparation of octafluoro-{2,2}paracyclophane
AU6856796A (en) Des-arg9-bk antagonists
AP9801212A0 (en) Tetrahydroquin olinesas NMDA antagonists
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
AU7458994A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
AU698867B2 (en) Fused imidazo 1,2-a pyridines
AU1660397A (en) Novel pyrimido(1,2-a)indoles
AU5322994A (en) Fibrinogen receptor antagonists
AU4698889A (en) New substituted pyrido(2,3-d)pyrimidines
AU1373395A (en) Vpr receptor protein
AU2831392A (en) Substituted 1, 5-pentanediols and processes for the preparation thereof
AU641516B2 (en) Back-rest
AU6247490A (en) Nmda antagonists
AU2236192A (en) Janitorial apparatus